|
|
Biotech
|
|
||
Re: RLMD Phase 2 results Tues Oct 15 CCShare count estimate with all warrants and options exercised is somewhere between 17-20 million. Value of an anti-depressant adjunct with rapid and robust anti-depressant effects... $8Billion (Take a stab) That's $400/share. Plenty of upside here. |
return to message board, top of board |